Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants

NEXT STORY
Walmart to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Screening Test
PREV STORY
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs

FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in ...

author_avatar
NASDAQ Market News

VBL Therapeutics Announces Second Quarter 2018 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today VBL is well capitalized, cash ...

author_avatar
NASDAQ Market News

SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) ...

author_avatar
NASDAQ Market News